中新健康｜哈佛大学医学院荣休教授：中国药物研发已进入全新阶段-中新网

Resumen del corpus

Gregory L. Verdine, a distinguished professor from Harvard Medical School, stated that China's drug research has entered a new phase, particularly in drug discovery aided by artificial intelligence. He believes that the combination of China's strengths in scale, manufacturing, screening, and AI positions the country at the forefront of drug development. While current licensing deals often involve known targets, Chinese pharmaceutical companies can significantly improve drug properties. Verdine cautioned that future success depends on accepting greater risks in target selection, emphasizing that scientific capability is not a barrier, but rather the capacity of the capital market to accommodate this risk.